PASIREOTIDE-INDUCED HYPERGLYCEMIA IN
ACROMEGALY PATIENTS: EVALUATION OF PATHOPHISIOLOGICAL MECHANISMS AND EFFICACY OF ANTIDIABETIC TREATMENT by Grasso, Ludovica francesca Stella
 UNIVERSITÀ DEGLI STUDI DI NAPOLI “FEDERICO II” 
 
DOTTORATO DI RICERCA IN 
TERAPIE AVANZATE MEDICO-CHIRURGICHE 
XXXI CICLO 
 
TESI DI DOTTORATO DI RICERCA  
 
 
 
 
PASIREOTIDE-INDUCED HYPERGLYCEMIA IN 
ACROMEGALY PATIENTS: EVALUATION OF 
PATHOPHISIOLOGICAL MECHANISMS AND EFFICACY 
OF ANTIDIABETIC TREATMENT 
 
 
 
 
Relatore  Candidato 
Ch.ma Prof.  Ludovica F. S. Grasso 
Annamaria Colao  
 
 
 
 
 
ANNO ACCADEMICO 2018/2019 
 
 2 
 
 
 
 
 
 
 
                                                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
INDEX 
 
1. INTRODUCTION Page 4 
2. AIM Page 8 
3. PATIENTS AND METHODS Page 9 
3.1. Patients Page 9 
3.2. Study design 
3.3. Biochemical assessments 
Page 10 
Page 11 
3.4. Statistical analysis Page 12 
4. RESULTS Page 13 
4.1. Baseline 
4.2. Primary objective  
4.3. Secondary objective  
Page 13 
Page 13 
Page 16 
5. DISCUSSION  
 
Page 17 
6. CONCLUSION Page 24 
7. REFERENCES Page 25 
8. TABLES AND FIGURES Page 31 
 
 
 
 
 
 
 
 
 
 
     
 
 
 4 
 
1. INTRODUCTION 
Acromegaly is a slowly progressive disease resulting from the increased 
release of growth hormone (GH) and, consequently, insulin- like growth 
factor I (IGF-I), which in most cases is induced by a GH- secreting 
pituitary tumor (1). Prolonged exposure to hormone excess induces 
progressive somatic disfigurement and a wide range of systemic 
manifestations, resulting in an increased mortality (2-5). To reduce 
morbidity and normalize life expectancy to that of the general 
population, the key treatment goals are to achieve and maintain control 
of GH and IGF-I levels, reduce or stabilize tumor volume, preserve 
pituitary function, and prevent recurrence (2). Acromegaly treatment 
approaches, which include surgery, radiotherapy and medical therapy, 
have changed considerably over time owing to improved surgical 
procedures, development of new radiotherapy techniques and availability 
of new medical therapies (1,6).  
Medical therapy is currently an important treatment option and can even 
be the first-line treatment in patients with acromegaly who will not 
benefit from or are not suitable for first-line neurosurgical treatment (2). 
First-generation somatostatin analogs (SSA, octreotide long-acting 
release and lanreotide Autogel) are the first- line medical therapy in most 
patients with acromegaly (2). The biochemical control rate is ~55% for 
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patients treated with first-generation SSA, although large differences in 
the hormonal efficacy of SSA between different case series have been 
reported (7,8). Moreover, first-generation SSA induce tumor shrinkage in 
up to 80% of patients, and the reduction in tumor volume is greater 
when SSA are used as first- line therapy (9,10). However, despite the 
clinical success of first-generation SSA in the treatment of acromegaly, 
approximately half of patients remain inadequately controlled, resulting 
exposed to the deleterious effects of hormone hypersecretion, increasing 
mortality risk (11-19). Alternative medical therapies are available, 
including dopamine agonists (DAs) and the GH receptor antagonist 
pegvisomant (PEG, 2). DAs have a limited role in acromegaly and are 
mostly used as a first-line medical therapy in patients with mildly 
elevated GH and IGF-I levels or are used in combination with first- 
generation SSA in patients who are partially resistant to SSA, being 
effective in ~35% of patients (2,20,21). PEG is indicated after surgery 
failure and/or resistance to first-generation SSA treatment, either as a 
monotherapy or in combination with SSA, with IGF-I levels being 
normalized by PEG therapy in roughly 60–97% of patients (22-25). 
However, PEG does not reduce GH levels and tumor volume. Thus, 
alternative therapeutic options are needed. The second-generation SSA 
pasireotide-LAR (PAS) represents the last approved medical therapy in 
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acromegaly. PAS, a multireceptor-targeted somatostatin analog, has a 
high binding affinity for SSTR1, 2, 3, and 5 (exhibiting a 39-fold higher 
binding affinity for SSTR5 compared with octreotide, 26), with more 
profound suppression of GH and IGF-I than octreotide (27,28). PAS 
have been approved by both the Food and Drug Administration and the 
European Medicines Agency in 2014 for the treatment of acromegaly 
when surgery is unsuccessful or is not an option and when treatment 
with first- generation SSA is not effective in controlling acromegaly, 
especially in patients with clinically relevant residual tumor and/or 
clinical concern of tumor growth (6,29). In a randomized, Phase III 
study in medically naive patients with acromegaly (30), PAS 
demonstrated superior efficacy in achieving biochemical control over 
octreotide LAR. More recently, in the PAOLA study (31), PAS provided 
superior efficacy versus continued treatment with first-generation SSA 
octreotide LAR or lanreotide Autogel (control group) in patients with 
inadequately controlled acromegaly. Furthermore, a >25% reduction in 
tumor volume occurred in more patients receiving PAS than in patients 
receiving first-generation SSA (31). Thus, PAS is a valid new treatment 
option for patients with acromegaly, especially those who are resistant to 
first- generation SSA(1,29). In both studies (30,31), the safety profile of 
PAS was generally similar to that of first-generation SSA, except for a 
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higher frequency and degree of hyperglycemia. In the PAOLA study 
(31), all grade hyperglycemia-related adverse events were reported in 
67% of patients on PAS 40 mg, 61% of patients on PAS 60 mg, and in 
30% of patients on first-generation SSA, whereas diabetes mellitus (DM) 
was reported in 21%, 26% and 8% of patients, respectively. However, 
knowledge about pathophysiology of PAS-induced hyperglycemia is still 
matter of debate. The mechanism of PAS-induced hyperglycaemia has 
been explored in two studies (32,33) conducted in healthy human 
volunteers. These investigations have demonstrated that PAS acts on the 
incretin system, known to modulate insulin secretion, as it inhibits 
insulin secretion simultaneously with the decrease in glucagon, glucagon-
like peptide 1 (GLP-1), and glucose-dependent insulinotropic 
polypeptide (GIP) secretion.  However, pathophysiological effects of 
pasireotide on glucose metabolism are yet to be completely elucidated, 
and consensus on the best management of PAS-induced hyperglycemia 
in acromegalic patients has still to be defined. 
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2. AIM  
The current study aimed at: 
1. Investigating the effects of long-term PAS treatment on 
glucose metabolism, besides GH and IGF-I control, by 
evaluating the clinical management of hyperglycemia 
adverse events in acromegalic patients participating to the 
PAOLA study, followed in two Italian referral Centers 
(University Federico II of Naples, Università Cattolica del 
Sacro Cuore, Rome).  
2. Investigating the role of metabolic parameters (weight, 
BMI, fasting glucose and HbA1c levels) and markers of 
disease activity (GH, IGF-I, duration of PAS treatment) as 
potential predictors of hyperglycemia development.  
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3. PATIENTS AND METHODS 
3.1. Patients  
The current study considered male and female patients aged 18 years or 
older with inadequately controlled acromegaly, defined as five-point, 2 h 
mean GH concentration >2.5 µg/L and IGF-1 concentration >1.3 
times the sex-adjusted and age adjusted upper normal limit, as per 
protocol (31). Eligible patients had received either 30 mg octreotide LAR 
or 120 mg lanreotide Autogel as monotherapy continuously for 6 
months or longer before screening (31). Patients who had received 
combination therapy with a PEG or DAs were eligible, but these drugs 
had to be discontinued at least 8 weeks before screening (31). Patients 
could have received previous pituitary surgery (31).  
The exclusion criteria (31) were the following: 
– Patients with compression of the optic chiasm causing acute clinically 
significant visual field defects. 
– No pituitary irradiation within the last 10 years. 
– Patients with poorly controlled diabetes mellitus (HbA1C > 8%). 
– Patients treated for < 6 months with PAS. 
The study was done in accordance with the Declaration of Helsinki, and 
an independent ethics committee or institutional review board for each 
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study site approved the study protocol. All patients provided written 
informed consent prior to study participation. 
 
3.2. Study design 
The current is a prospective, multicenter, randomized, parallel-group, 
phase 3 study (31). After a 4-week screening period, patients were 
randomized to receive double blind PAS 40 mg every 28 days for 24 
weeks, or double-blind PAS 60 mg every 28 days for 24 weeks (group 1), 
or to continue on the same treatment with open label octreotide LAR 30 
mg or lanreotide Autogel 120 mg every 28 days for 24 weeks (group 2). 
Transient dose decreases were permitted for tolerability issues in all 
treatment arms (31).  
All patients who completed the 6-month treatment (core study) were 
eligible to participate in the extension phase, except for patients who 
achieved biochemical control in the open-label active control arm (31). 
All patients in the active control group who remained uncontrolled at 
week 24 had the opportunity to switch to PAS in the extension phase 
(31). 
For the current study primary objectives were to assess changes in 
glucose homeostasis biomarkers (fasting plasma glucose [FPG] and 
HbA1c) during long-term (mean time 34 months) treatment with PAS, 
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regardless from PAS dose, and the management of hyperglycemia-related 
adverse events. As for the Paola study (31), the secondary endpoint was 
the proportion of patients achieving biochemical control, defined as 
GH< 2.5 µg/L and normalization of sex- and age-adjusted IGF-I during 
long-term treatment, regardless from PAS dose. 
 
3.3 Biochemical assessments 
Blood samples for assessment of total IGF-I were taken at the same 
visits as for the assessment of mean GH level, before the administration 
of study drug. Samples were analyzed as follows: GH was assessed as the 
mean of an average of five individual measurements taken pre-dose at 0, 
30, 60, 90, and 120 min within a 2-h time period after 1 h at rest at the 
hospital and was measured using the Siemens Immulite 2000 S/N 1832 
assay by a central contract research organization (Quest Diagnostics 
Clinical Trials, Valencia, CA, USA). IGF-1 were analysed from individual 
serum samples using the Siemens Immulite 2000 S/N 1832 IGF-1 assay 
(Quest Diagnostics Clinical Trials, Valencia, CA, USA); FPG and HbA1c 
were centrally analyzed (Quest Diagnostics Clinical Trials, Valencia, CA, 
USA) by spectrophotometry using an Olympus AU 640/2700/5400 
analyser and by high-performance liquid chromatography (HPLC) using 
a TOSOH G7/G8 automated HPLC analyser, respectively. Analyses 
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were conducted on patients who had available samples. Hyperglycaemia 
was defined as one post-baseline FPG measurement of >100 mg/dL or 
necessity of antidiabetic medication at any time during this study. 
Impaired fasting glucose (IFG) was defined as fasting glucose levels > 
100 mg/dl, impaired glucose tolerance (IGT) was defined as glucose 
levels of 140 to 199 mg/dL after an oral glucose tolerance test (OGTT). 
 
3.4. Statistical analyses 
Data were analyzed using SPSS Software for Windows, version 20.0 
(SPSS, Inc., Cary, NC package). Data are reported as Mean±SD, unless 
otherwise specified. The comparison between the numerical data before 
and after treatment with first-generation SSA and PAS was made by 
non-parametric Wilcoxon test. In each treatment arm, the comparison 
between the numerical data during treatment with first-generation SSA 
and PAS was made by non-parametric Friedman test corrected by Dunn 
test when necessary. The comparison between prevalence was performed 
by χ2 test corrected by Fisher exact test when necessary. The correlation 
study was done by calculating the Pearson’s correlation coefficients. 
Regression analysis was done to evaluate the association of PAS-induced 
hyperglycemia adverse events with metabolic profile and/or with 
hormonal levels. Significance was set at 5%. 
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4. RESULTS 
4.1. Baseline 
A total of 31 patients entered the present study, including 18 randomized 
to PAS (group 1), and 13 to continued treatment with octreotide LAR 30 
mg or lanreotide Autogel 120 mg (group 2). Table 1 shows patient 
demographics characteristics, and disease history at baseline. Twelve 
patients (61%) in group 1 and nine (69%) in group 2 had previously 
received surgery (p=0.93). Pre-existing diabetes mellitus was found in 
five patients (27.7%) in group 1 and one (7.7%) in group 2 (p=0.34), 
whereas pre-existing prediabetes, defined as IGT or IFG, was seen in 
one patients (5.5%, IGT) in group 1 and in three patients (23.1%, 2 IGT, 
1 IFG) in group 2 (p=0.34).  
4.2. Primary objective 
Changes in glycemic metabolism 
Patients were treated with PAS for a mean time of 34 months (6-67 
months). In group 1, mean FPG and HbA1c concentrations significantly 
increased (p=0.005) after 6 months of treatment, at the end of the core 
phase, further increasing until the last follow-up (p=0.0005). In group 2, 
mean FPG and HbA1c concentrations remained similar to that of the 
baseline levels in the core phase, but they significantly increased in the 
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extension phase at 6 months of PAS treatment (p=0.005), further 
augmenting until the last follow-up (p=0.005, figure 1).  
Hyperglycemia-related adverse events were reported in 15 patients 
(83.3%) in group 1, occurring after a mean time of 5 months (1-16 
months); all cases were of mild-to-moderate severity, defined as grade 2-
3. In all patients hyperglycemia-related adverse events were judged to be 
related to study drug. One patient required treatment discontinuation 
because of diabetes adverse event. Four out five patients with diabetes 
mellitus at baseline (80%) reported worsening of hyperglycemia during 
PAS treatment. One patient with IGT at baseline (100%) developed 
overt diabetes mellitus. Six (50%) and four (33.3%) patients with normal 
glucose tolerance at baseline developed IFG and diabetes mellitus, 
respectively, during PAS treatment. In group 2, three (23%) patients 
reported hyperglycemia-related adverse events during the core phase 
(during first-generation SSA therapy), after a mean time of two months. 
Particularly, overt diabetes mellitus occurred in two patients (15.3%) 
with baseline normal glucose tolerance and in one patient (7.7%) with 
IGT at baseline. All cases were of mild severity, defined as grade 1. 
During the extension phase, nine patients (69.2%) reported 
hyperglycemia-related adverse events after a mean time of seven months 
(2-17 months) from the beginning of PAS treatment. One diabetic 
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patient (33.3%) reported worsening hyperglycemia. Among patients with 
normal glucose tolerance at baseline, three (16.6%) developed pre-
diabetes (2 IFG, 1 IGT), and two patients (15.3%) developed overt 
diabetes mellitus during PAS treatment.  All cases were of mild-to-
moderate severity, defined as grade 2-3, and were judged to be related to 
study drug. No patient required treatment discontinuation because of 
hyperglycemia adverse event. Table 2 shows hyperglycemia related 
adverse events according to baseline diabetic status. 
The risk to develop hyperglycemia correlated neither with baseline BMI, 
weight, GH, IGF-I, glucose and HbA1c levels, or duration of PAS 
treatment (p=0.41). Similarly, glucose status did not significantly 
correlate with biochemical control at the last follow-up (p=0.66). 
Effect of antidiabetic drugs on glucose control 
At study entry, three patients (16.6%) in group 1 and one patient (7.7%) 
in group 2 were already treated with antidiabetic drugs. In group 1, 
starting of new antidiabetic treatment was required in eight patients (44.4 
%, figure 2) throughout the study, and metformin was the drug of choice 
in all these patients. Four (50%) out eight patients did not control 
glucose and HbA1c levels despite metformin monotherapy, needing 
further therapies. In fact, metformin was associated with DPP-4 
inhibitor in one patient (25%), GLP-1 agonist in two patients (50%), and 
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GLP-1 agonist and glargine insulin in one patient (25%) to control 
hyperglycemia. Two patients previously treated with antidiabetic drugs (1 
patient with metfomin plus glargine insulin, and 1 patient with glargine 
insulin monotherapy) needed a dose adjustment to control 
hyperglycemia. In group 2, one patient (7.7%) started metformin during 
the core phase. During the extension phase, starting of new antidiabetic 
treatment was required in seven patients (53.8%), and metformin was the 
drug of choice in all these patients. Three (42.8%) out seven patients did 
not control glucose and HbA1c levels despite metformin monotherapy, 
requiring further therapies. In fact, metformin was associated with DPP-
4 inhibitor in one patient (33.3%), GLP-1 agonist in two patients 
(33.3%), and GLP-1 agonist and detemir insulin in one patient (33.3%) 
to control hyperglycemia. Figure 3 shows the antidiabetic drugs used 
during the long-term treatment in group 1 and group 2, respectively.  
 
4.3. Secondary objective 
Biochemical control 
Biochemical control, defined as 5-point, 2 h mean growth hormone 
concentration less than 2.5 µg/L and normalized IGF-I concentrations, 
was achieved by nine patients (50%) in group 1 at 6 months, compared 
with no patients in group 2 (p=0.009). Eight patients (44.4%) in group 1 
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and five (38.4%) in group 2 achieved biochemical control, respectively, 
after 12 months of treatment (p=0.97), whereas nine (50%) and seven 
(53.8%) patients in group 1 and group 2, respectively, achieved 
biochemical control at the last follow-up (mean time 34 months, p=0.84, 
figure 4). In group 1, mean GH concentrations significantly decreased 
from baseline to month 6 (p<0.0005) and month 12 (p<0.005) and 
remained stable until the last follow-up. Mean IGF-I concentration 
significantly decreased from baseline to month 6 (p<0.005) and 
remained stable at 12 months until the last follow-up. In group 2, mean 
GH and IGF-I concentrations slightly but not significantly decreased 
during the core phase. During the extension phase, mean GH and IGF-I 
concentration significantly decrease from baseline to month 12 
(p<0.005), further decreasing until the last follow-up (p<0.0005, figure 5).  
 
5. DISCUSSION 
The present study first reports the long-term effect of PAS on glucose 
metabolism and biochemical control. Differently from the PAOLA study 
(31), where glucose homeostasis was relatively undisturbed throughout 
the treatment period in those patients receiving continued therapy with 
either octreotide LAR or lanreotide Autogel, in the present study a rapid 
initial increase in FPG and HbA1c levels was observed in all patients for 
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both treatment arms following the first 6 months of treatment with PAS, 
inducing a further increase over time, until the last follow-up. 
Hyperglycemia-related adverse effects were reported in 83.3% and 69.2% 
of patients during PAS therapy in group 1 and group 2, respectively. 
Conversely, in the PAOLA study (31) mean glucose and HbA1c levels 
were reported to initially increase rapidly after PAS treatment starting; 
subsequently glucose and HbA1c levels plateaued, remaining stable to 6 
months. Consequently, the rate of hyperglycemia found in the current 
investigation was higher than that reported in the PAOLA study (31), 
where 67% of patients reported hyperglycemia-related adverse events. 
These findings may be explained considering the different treatment 
duration in the current study as compared to the Paola one (only 6 
months of therapy with PAS), and hypothesizing long-term effects of 
PAS on glucose metabolism, since in the present study hyperglycemia-
related adverse events occurred up to 17 months after PAS treatment 
starting.  
Given the physiological role of natural somatostatin, as well as the SSTR 
binding profile of PAS (34), disturbances in glucose metabolism are not 
unexpected during treatment with PAS. Endocrine cells of the pancreas 
consist of α-, β-, and δ-cells, which secrete glucagon, insulin, and 
somatostatin, respectively, in response to changes in blood glucose (34). 
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Insulin and glucagon are antagonistic hormones that regulate glucose 
uptake and metabolism, while localized release of somatostatin 
suppresses secretion of insulin and glucagon (34). In humans, glucagon-
producing α-cells predominantly express SSTR2 (35), whereas SSTR5 
and SSTR2 are found mainly on insulin-producing β-cells (36). As PAS 
binds with higher affinity to SSTR5 than to SSTR2 (34), insulin secretion 
is substantially reduced while glucagon secretion is less markedly 
suppressed, resulting in an overall increase in glucose levels. Preclinical 
studies (37) showed that pasireotide and octreotide suppressed insulin 
secretion to a similar degree, whereas pasireotide was a weaker inhibitor 
of glucagon secretion than octreotide. Indeed, the SSTR5/SSTR2 
activation ratio has been hypothesized to be the main driver of 
pasireotide-induced hyperglycemia (37). Interestingly, Schmid et al. (37) 
showed that co-administration of octreotide and pasireotide in rats 
negated the hyperglycemia seen with pasireotide alone, implying that 
strong activation of SSTR2 by octreotide was sufficient to restore 
normoglycemia. The mechanism of pasireotide-induced hyperglycemia 
has been further explored in two studies (32,33) conducted in healthy 
human volunteers. Henry et al. (32) reported that twice-daily 
subcutaneous pasireotide administration of 600 or 900 µg significantly 
decreased plasma levels of insulin, glucagon-like peptide 1 (GLP-1), and 
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glucose-dependent insulinotropic-polypeptide. Glucagon secretion was 
only minimally affected, and insulin sensitivity was unaffected. In the 
second study (33), the incretin-based antihyperglycemic agents liraglutide 
(GLP-1 agonist) and vildagliptin (DPP-4 inhibitor) were shown to 
effectively ameliorate hyperglycaemia when co-administered with 
pasireotide. Taken together with the aforementioned studies, the role of 
the incretin system affecting insulin secretion is strongly implicated in 
the mechanism of action of pasireotide.  
The results of the present study confirm the direct effect of PAS in 
inducing hyperglycemia, independently from patients baseline 
characteristics and disease control. In particular, the risk to develop 
hyperglycemia resulted not significantly related either to baseline BMI, 
weight, GH, IGF-I, glucose and HbA1c levels, or duration of PAS 
treatment. Similarly, glucose status did not significantly correlate with 
biochemical control at the last follow-up. In contrast, a recent study by 
Schmid et al. (38) investigating the mechanism of action of PAS in 198 
patients who completed the PAOLA study, has reported that patients 
with baseline FPG >100 mg/dL experienced higher levels of FPG and 
HbA1c after treatment with PAS, compared with those with 
normoglycemia at baseline, supporting the hypothesis of baseline glucose 
status as a potential predictive factor for the development of 
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hyperglycemia during PAS treatment. The inconsistency between 
findings from results of the current study and those of the study by 
Schmid  (38) can be attributable to the smaller number of patients 
analyzed in the present study.   
In the present study, 44.4% in group 1 and 53.8% of patients in group 2, 
respectively, required to start antidiabetic drugs during PAS treatment, 
and metformin was the treatment of choice in all these patients. In 
patients not adequately controlled by metformin monotherapy, DPP-4 
inhibitors and GLP-1 agonists were administered to control 
hyperglycemia, followed by insulin. Similar findings have been recently 
reported (39) in a sub-analysis of the phase III, randomized study in 
medically naive patients with acromegaly (30), evaluating patients treated 
with PAS who started antidiabetic medication during the study. 
Metformin was the most commonly initiated antidiabetic medication 
during the study, in line with its role as first-line medical therapy for 
glycemic management. Metformin monotherapy (n= 24) or in 
combination with other oral antidiabetic medication (n= 19) was found 
to be effective in controlling hyperglycemia-related adverse events (39). 
Although metformin exerts its therapeutic effect mainly by reducing 
hepatic glucose production, it also reduces DPP-4 activity and increases 
GLP-1 secretion (40), resulting the best choice in patients with PAS-
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induced hyperglycemia. Moreover, a previous study (33) conducted in 
healthy male volunteers evaluated various strategies for managing PAS-
induced hyperglycemia. Ninety volunteers were randomized to receive 
either pasireotide s.c. alone or in combination with metformin, 
nateglinide (meglitinide), vildagliptin (DPP-4 inhibitor), or liraglutide 
(GLP-1 agonist) for 7 days. On Day 7, the glucose area under the curve 
increased by 69% from baseline in the pasireotide -only group. The 
increase from baseline was substantially lower in the groups that were 
concomitantly treated with metformin (60%), nateglinide (49%), 
vildagliptin (38%), and liraglutide (19%), indicating that GLP-1 agonists 
and DPP-4 inhibitors might be the most viable antidiabetic agents to co-
administer with pasireotide in order to manage PAS-induced 
hyperglycemia in patients not controlled by metformin monotherapy 
(33). A recent study (41) on patients receiving PAS for medical treatment 
of Cushing’s disease has investigated the best management of PAS-
induced hyperglycemia, and has suggested to administer treatment with 
metformin as early as possible after occurrence of hyperglycemia and, if 
not controlled on metformin, with DPP-4 inhibitor or GLP-1 agonist, 
keeping therapy with insulin in patients experiencing the failure of oral 
antidiabetic drugs. On the basis of the association between PAS and 
hyperglycemia, these recommendations could also be applicable to 
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patients with acromegaly, even though further studies are needed to 
determine the best management for hyperglycemia in acromegalic 
patients.  
The therapeutic approach for diabetes mellitus used in the present study 
confirm that PAS-induced hyperglycemia is correctly managed in clinical 
practice in the two Italian referral centers participating to the current 
study. Moreover, approximately half of patients treated with PAS did not 
receive antidiabetic medication at any time during this study, therefore 
leading to the conclusion that a substantial proportion of patients with 
acromegaly do not experience disturbances in glucose homeostasis 
during PAS treatment so that to require the initiation of antidiabetic 
medication. Whether glucose response to PAS treatment can be 
predicted is still matter of debate. Besides FPG at baseline, other clinical 
and metabolic parameters, such as patient age and sex, disease duration, 
previous medical or surgical treatment, gonadal status, and other 
concomitant metabolic or cardiovascular complications, might play a role 
as modulator of glucose profile during PAS treatment, and further 
studies are required to better elucidate the burden of such factors as 
predictors of glycaemic homeostasis while on PAS therapy. 
 24 
 
Altogether, the results of these studies suggest that blood glucose 
concentrations should be closely monitored in patients treated with PAS 
and that antidiabetic treatment should be promptly initiated. 
The secondary endpoint of the present study was the proportion of 
patients achieving biochemical control, defined as GH< 2.5 µg/L and 
normalization of sex- and age-adjusted IGF-I during long-term 
treatment, as for the PAOLA study. In line with the results of the 
PAOLA study (31), the present study confirms the superior efficacy of 
PAS over continued treatment with first-generation SSA in controlling 
acromegaly up 67 months of treatment. In particular biochemical control 
at 6 months (core phase) was achieved in 50% of patients in group 1, 
compared with no patients in group 2. At 12 months (extension phase) 
44.4 % of patients in group 1 and 38.4% of those in group 2 achieved 
biochemical control; the proportion raised up to 50% and 53.8% of 
patients in group 1 and group 2, respectively, at the last follow-up. The 
percentage of biochemical control reported in the present study resulted 
even higher than the PAOLA study (31), where 18% of patients were 
controlled after 6 months of treatment with PAS. This differences can be 
explained considering the longer treatment duration in the current study 
(mean 34 months) as compared to the PAOLA study (6 months), 
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therefore hypothesizing a progressive additive effect of PAS on GH and 
IGF-I normalization.  
 
6. CONCLUSION 
The results of the present study confirm the known negative effect of 
PAS on glucose metabolism, however treatment intensification with 
DPP4 inhibitor and GLP-1 agonist resulted in good glycemic control in 
most patients. Moreover, a considerable number of acromegaly patients 
resistant to first-generation SSA may benefit from treatment with 
monthly injections of PAS, since in this cohort over 50% of patients 
achieved long-term normalization of GH and IGF-I levels. Further 
studies are needed to deeply evaluate the mechanism of PAS-induced 
hyperglycemia in acromegalyc patients, investigating the effect of PAS on 
insulin secretion and hepatic/peripheral insulin sensitivity. 
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9. TABLES AND FIGURES 
 
 Group 1 Group 2 p 
Patient n. 18 13 0.61 
Age (years) 44.8 ±9.6 47.7 ± 11.1 0.44 
Previous surgery 12 (61%) 9 (69%) 0.55 
Baseline GH (ug/L) 22.4 ± 47.7 12.04 ± 23.5 0.55 
Baseline IGF-I (ng/ml) 540.2±218.5 696.9±320.5 0.61 
Baseline fasting glucose 
(mg/dl) 
104±32 102±10 0.66 
Baseline HbA1c 5.82±0.45 5.86±0.27 0.62 
Table 1: Patients’ profile at study entry. GH: growth hormone. 
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Figure 1: Fasting glucose and HbA1c levels modifications during long-term treatment in 
group 1 and group 2. 
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GROUP 1 BASELINE LAST FU 
NGT 12 (66.6%) 2 (11.1%) 
Pre-DM 1 (5.5%) 6 (33.3%) 
DM 5 (27.7%) 10 (55.5%) 
GROUP 2 BASELINE LAST FU 
NGT 9 (69.2%) 2 (15.3%) 
Pre-DM 3 (23.1%) 3 (23.1%) 
DM 1 (7.7%) 8 (61.5%) 
Table 2: Hyperglycemia-related adverse events according to baseline glycemic status. 
NGT= normal glucose tolerance; DM= diabetes mellitus. 
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Figure 2: Percentage of patients treated with antidiabetic drugs in group 1 and group 2. 
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Group 2 
Figure 3: Antidiabetic drugs used during long-term treatment in group 1 and group 2. 
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Figure 4: Percentage of patients achieving biochemical control (5-point, 2 h mean growth 
hormone concentration less than 2.5 µg/L and normalised IGF-I concentrations) during 
long-term treatment in group 1 and group 2. 
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Figure 5: GH and IGF-I levels reduction during long-term treatment in group 1 and 
group 2. 
